- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04593836
Antiperistaltic Effect and Safety of L-menthol in the Elderly With Contraindication to Buscopan (Non-Buscopan)
Antiperistaltic Effect and Safety of L-menthol and Placebo for Upper GI Endoscopy in the Elderly With Contraindication to Buscopan: a Prospective, Randomized, Double-blind Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Endoscopy is a important tool for diagnosis and treatment of gastrointestinal diseases. Effective inhibition of gastrointestinal motility during examination is important to achieve good results and quality.
Traditionally, hyoscine-N-butylbromide (Buscopan) is the most commonly used drugs that inhibit intestinal peristalsis. But the side effects of drugs were mentioned in many studies, such as arrhythmia, increased glaucoma, dysuria in patients who have benign prostatic hypertrophy and allergic reactions, and may even cause anaphylactic shock. Peppermint oil is the extract of the natural plant (Mentha X piperita L) which was growth in North America and Europe. L-menthol is main component of peppermint oil. In animal experiments, peppermint oil had effect of calcium channel blockers and cause gastrointestinal smooth muscle relaxing effect. Clinically, peppermint oil preparations were used to relieve stress headache, non-ulcer dyspepsia and irritable bowel syndrome. The oral or intestinal local spraying of peppermint oil or L-menthol showed inhibition of intestinal peristalsis in many studies, and improved colonoscopy, barium enema, retrograde cholangiography , and upper gastrointestinal endoscopy examination.
With the aging of the population of Taiwan and the universality of endoscopy for elderly patients, the safety of endoscopy in elderly patients has more and more attention. According to ASGA guidelines, age is not a contraindication for endoscopy. But 50% of elderly patients have contraindications for hyoscine-N-butylbromide use. Therefore, effort to find alternative medicine to improve quality of endoscopy in elderly patients is necessary. Therefore, the investigators design a research for comparing effect and safety of L-menthol and placebo in elderly patients who have contraindication of hyoscine-N-butylbromide.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 11217
- Recruiting
- Taipei Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- >65 years old
- routine endoscopic examination
- Contraindication to Buscopan(such as arrhythmia, glaucoma, benign prostatic hyperplasia, ischemic heart disease...)
Exclusion Criteria:
- Status post gastric or duodenal surgery
- The patient with critical illness are not suitable for the endoscopic examination
- Upper gastrointestinal bleeding
- Gastric tumor
- Gastric or duodenal ulcers are larger than 2 cm
- Severe pyloric obstruction or deformity
- Cancer patients received chemotherapy or radiation therapy
- Had peppermint allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: L-menthol
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
|
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
Other Names:
|
|
PLACEBO_COMPARATOR: Placebo
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
|
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peristaltic grade
Time Frame: 10 mins
|
Grade 1: no peristalsis; grade 2: mild peristalsis; grade 3: moderate peristalsis; grade 4: vigorous peristalsis; grade 5: markedly vigorous peristalsis.
|
10 mins
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pylorus contraction ratio
Time Frame: 3 mins
|
Contraction ratio (%)= [(maximal pyloric ring diameter - minimal pyloric ring diameter)/minimal pyloric ring diameter] x 100
|
3 mins
|
|
Pylorus opening ratio: maximum and minimum
Time Frame: 3 mins
|
Opening ratio (%) = [(pyloric ring diameter after administration of the antispasmodic agent - pyloric ring diameter before administration of the antispasmodic agent) / pyloric ring diameter before administration of the antispasmodic agent] x 100
|
3 mins
|
|
Adverse effect of patients
Time Frame: 48 hours
|
record all adverse effect after study, include abdominal pain, heart burn, headache, allergy, etc.
|
48 hours
|
|
VAS score of patient about procedure
Time Frame: 10 mins
|
VAS score 1-10 about the painful sensation of patient during procedure
|
10 mins
|
|
Satisfaction of endoscopist
Time Frame: 10 mins
|
Four score was evaluated: very easy, easy, slightly difficult and difficult about the procedure due to gastric spasm
|
10 mins
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V101A-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Gastrointestinal Endoscopy
-
Mahmoud Mohammed Osman AliAssiut UniversityCompletedUpper Gastrointestinal EndoscopyEgypt
-
Carol Davila University of Medicine and PharmacyCompletedUpper Gastrointestinal EndoscopyRomania
-
Carol Davila University of Medicine and PharmacyCompletedUpper Gastrointestinal EndoscopyRomania
-
Ain Shams UniversityCompletedUpper Gastrointestinal EndoscopyEgypt
-
University Hospital, CaenCompletedUpper Gastrointestinal EndoscopyFrance
-
Ain Shams UniversityNot yet recruitingAnesthesia | Upper Gastrointestinal Endoscopy
-
Sevim Şenol KarataşCompletedUpper Gastrointestinal Endoscopy | Intraocular Pressure ChangesTurkey (Türkiye)
-
Jiangsu HengRui Medicine Co., Ltd.CompletedSedation in the Upper Gastrointestinal EndoscopyChina
-
Zagazig UniversityCompletedTopical Anesthesia | Upper Gastrointestinal Endoscopy | Intravenous SedationEgypt
-
Zagazig UniversityCompletedTopical Anesthesia | Upper Gastrointestinal Endoscopy | Intravenous SedationEgypt
Clinical Trials on L-menthol
-
Region SkaneBlekingesjukhuset, Karlskrona; Blekinge Institute of TechnologyNot yet recruiting
-
Region SkaneLund University; Blekingesjukhuset, Karlskrona; Blekinge Institute of TechnologyRecruitingInterstitial Lung Disease (ILD)Sweden
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA); Brown University; National Institutes... and other collaboratorsCompletedSmoking (Tobacco) AddictionUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); University of MinnesotaRecruitingSmoking Prevention and ControlUnited States
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); Food and Drug Administration (FDA)Recruiting
-
University of MinnesotaNational Institute on Drug Abuse (NIDA)CompletedTobacco Use DisorderUnited States
-
Region SkaneLund UniversityCompletedChronic Obstructive Pulmonary Disease (COPD)Sweden
-
University of PennsylvaniaNational Cancer Institute (NCI); National Institutes of Health (NIH); National...CompletedCigarette Smoking ToxicityUnited States
-
University of Sao PauloUniversidade Estadual de LondrinaCompleted